Results per Page:
New biomarker could one day help tailor immunotherapy for Merkel cell carcinoma
Helps explain why only certain MCC patients respond to immune checkpoint inhibitors, could point toward new strategies to improve treatment responses
Rethinking immunotherapy dosing frequency for better cost, time, and life savings!
From the Bhatia group, Clinical Research Division
Reducing frequency of immunotherapy dosing could save money and time, keep patients on therapy longer
Study of immune checkpoint inhibitor dosing in patients with advanced skin cancers could help guide long-term treatment plans
Cancer care: From ‘sledgehammer’ to precision cellular therapy
AACR progress report: new immunotherapies improve outcomes, but access to care and clinical trials for many still lags